Lots of questions are being raised.
So, as Resverlogix investors, would a negative knee-jerk reaction to this research article be warranted at this point in time? I'm also wondering if the results of their work has been out there for awhile now...and is that increase in the short position somehow tied to this? Is that why we've had no news of the first patient being dosed?
On the other hand, I have an issue with the work by Krogan and his associates:
Why, after including apabetalone on their list, did they now exclude it in their subsequent study? They refererence the study done by Mills, so they surely are aware of it.
So, has this been a cause of concern for months now, and the Resverlogix team has kept this quiet...or is that team, and the work done by the Aussies and the work done by the U of Nebraska way ahead of where the authors of this article are ...specifically as it relates to apabetalone?
JQ1 and ABBV-744...wonder what research the Aussie and U of Nebraska teams have done on them?
It would be great to hear Dr. Wong or one of our scientists address all of this.
Study they referenced:
Mills, R.J., Humphrey, S.J., Fortuna, P.R.J., Lor, M., Foster, S.R., Quaife-Ryan, G.A., Johnston, R.L., Dumenil, T., Bishop, C., Rudraraju, R., et al. (2021). BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection. Cell 184, 2167–2182 e2122.
